Multiple Myeloma Clinical Trials in Chapel Hill, North Carolina
27 recruitingChapel Hill, North Carolina
Showing 1–20 of 27 trials
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled116 locationsNCT07391657
Recruiting
Phase 2Phase 3
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple Myeloma
AbbVie660 enrolled49 locationsNCT07095452
Recruiting
Phase 2
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 2
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
CancerMultiple Myeloma
UNC Lineberger Comprehensive Cancer Center50 enrolled5 locationsNCT05145400
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled181 locationsNCT02693535
Recruiting
Phase 2
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company230 enrolled52 locationsNCT06297226
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Multiple Myeloma
GlaxoSmithKline152 enrolled30 locationsNCT05714839
Recruiting
Phase 1
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Refractory Multiple MyelomaRelapsed Multiple Myeloma
Opna Bio LLC130 enrolled12 locationsNCT06433947
Recruiting
Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 2
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting
Phase 1
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Multiple Myeloma
Poseida Therapeutics, Inc.275 enrolled23 locationsNCT04960579
Recruiting
Phase 1
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA200 enrolled32 locationsNCT05862012
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Breast CancerOvarian CancerLung Cancer+2 more
Carevive Systems, Inc.25 enrolled7 locationsNCT05974150
Recruiting
Phase 1Phase 2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Multiple Myeloma
AbbVie440 enrolled25 locationsNCT06892522
Recruiting
Not Applicable
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Multiple MyelomaLymphomaLeukemia+2 more
UNC Lineberger Comprehensive Cancer Center500 enrolled1 locationNCT06296368
Recruiting
Registry for Adults With Plasma Cell Disorders (PCD's)
Multiple MyelomaAmyloidosisSmoldering Multiple Myeloma+6 more
UNC Lineberger Comprehensive Cancer Center2,000 enrolled1 locationNCT03717844
Recruiting
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
LymphomaLeukemiaMyelodysplastic Syndromes+5 more
UNC Lineberger Comprehensive Cancer Center15,000 enrolled1 locationNCT01137643
Recruiting
Registry of Older Patients With Cancer
LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
UNC Lineberger Comprehensive Cancer Center3,000 enrolled7 locationsNCT01137825